Ifinatamab Deruxtecan Accelerated Filing Withdrawn
Daiichi Sankyo and Merck voluntarily withdrew the U.S. accelerated-approval application for ifinatamab deruxtecan in previously treated extensive-stage small-cell lung cancer after FDA discussions concluded that the supporting data, including Phase 2 IDeate-Lung01, did not…
